Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Using small RNA-Seq to identify differential small RNA content of bacterial outer membrane vesicles (OMVs) secreted by Pseudomonas aeruginosa in response to tobramycin exposure

ABSTRACT: Using small RNA-Seq to identify differential small RNA content of bacterial outer membrane vesicles (OMVs) secreted by Pseudomonas aeruginosa in response to tobramycin exposure

PROVIDER: PRJNA762296 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Using small RNA-Seq to identify differential small RNA content of bacterial outer membrane vesicles (OMVs) secreted by Pseudomonas aeruginosa in response to tobramycin exposure

Project description:Characterization of the sRNA content of OMVs harvested from Pseudomonas aeruginosa strain PA14 LB cultue with and without tobramycin (1ug/mL)

2021-09-12 | GSE183895 | GEO

Tobramycin Treatment of Planktonic Pseudomonas aeruginosa

2008-06-10 | GSE9991 | GEO

Identification of potential tobramycin-resistant mutagenesis of Escherichia coli strains after spaceflight

Project description:Background: This study aimed to explore potential tobramycin-resistant mutagenesis of Escherichia coli (E. coli) strains after spaceflight. Methods: A spaceflight-induced mutagenesis of multi-drug resistant E.coli strain (T1_13) on the outer space for 64 days (ST5), and a ground laboratory with the same conditions (GT5) were conducted. Both whole-genome sequencing and RNA-sequencing were performed. Results: A total of 75 SNPs and 20 InDels were found to be associated with the resistance mechanism. Compared to T1_13, 1242 genes were differentially expressed in more than 20 of 38 tobramycin-resistant E. coli isolates while not in GT5. Function annotation of these SNPs/InDels related genes and differentially expressed genes was performed. Conclusion: This study provided clues for potential tobramycin-resistant spaceflight-induced mutagenesis of E. coli.

2019-12-13 | GSE123795 | GEO

Porin-mediated passage of negamycin across the outer membrane of Escherichia coli

Project description:The rise of antimicrobial resistant pathogens calls for new antibacterial treatments, but potent new compounds are scarce. Development of new antibiotics is difficult, especially against Gram-negative bacteria, as here uptake is strongly hindered by the additional outer membrane. Most antimicrobial agents against Gram-negatives use the porin mediated pathway to cross the outer membrane, which limits the choice of an antibiotic, as it has to fit by size, charge and hydrophilicity. In E. coli, the major porins OmpF and OmpC are associated with antibiotic translocation and therefore also with unspecific antibiotic cross-resistance. In this regard, alternative uptake routes are of interest. We were interested in the uptake opportunities of the small, natural product antibiotic negamycin and thereby found new uptake pathways across the outer membrane of E. coli. Besides OmpF and OmpC, we investigated the role of the minor porins OmpN and ChiP in negamycin translocation. We detected an effect of OmpN and ChiP on negamycin susceptibility and confirmed passage by electrophysiological assays. The structure of OmpN was resolved in order to analyze the negamycin translocation mechanism by computational simulations. As abundancy of these minor porins was low in E. coli, their transcript levels were analyzed by RNA-Seq. Increased transcripts levels of ompN and chiP were observed upon negamycin treatment, hinting at a role in antibiotic uptake. These new, additional uptake pathways across the outer membrane of E. coli highlight the antibiotic potential of negamycin, especially as resistance development is low due to availability of multiple uptake routes at both the outer and inner membranes

2023-10-01 | GSE183363 | GEO

Secreted and membrane-associated genes

Project description:Large-scale identification of secreted and membrane-associated gene products using DNA microarrays. This study is described more fully in Diehn M et al.(2000) Nat Genet 25:58-62

2002-06-27 | E-GEOD-48 | biostudies-arrayexpress

Secreted and membrane-associated genes

2002-06-27 | GSE48 | GEO

Transcription profiling of planktonic pseudomonas aeruginosa exposed to tobramycin treatment

Project description:As a comparison to tobramycin-treated P. aeruginosa biofilms, we investigated the response of planktonic P. aeruginosa to tobramycin by microarray. Experiment Overall Design: We included 2 control (untreated) cultures and 2 tobramycin-treated cultures. We used mid-exponential phase cultures of P. aeruginosa PA14. Replicate cultures were incubated in the presence or absence of 5 Î¼g/mL tobramycin for 30 minutes at 37Â°C.

2008-06-21 | E-GEOD-9991 | biostudies-arrayexpress

Kristen-PAO1-anaerobic lethal concentrations tobramycin

Project description:To see the effects of tobramycin on Pseudomonas aeruginosa under anaerboc lethal conditions. RNA was isolated from 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 and 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 after being treated with 20 ug/ml tobramycin for 30 minutes.

2011-01-20 | E-FPMI-24 | biostudies-arrayexpress

Transcription profiling of Pseudomonas aeruginosa treated with tobramycin

Project description:This SuperSeries is composed of the following subset Series:; GSE9989: Tobramycin Treatment of P. aeruginosa Biofilms Grown on CFBE41o- Cells; GSE9991: Tobramycin Treatment of Planktonic Pseudomonas aeruginosa Experiment Overall Design: Refer to individual Series

2008-06-18 | E-GEOD-10030 | biostudies-arrayexpress

Kristen-PAO1 aerobic sub-inhibitory cond. tobramycin

Project description:To see the effect of sub-inhibitory concentrations of tobramycin on Pseudomonas aeruginosa grown under aerobic conditions. RNA was isolated form 4 biological repeats of P.aeruginosa grown to mid-log in cationic adjusted mueller hinton broth and 4 biological repeats of P.aeruginosa with the addition of 0.25ug/ml tobramycin in cationic adjusted mueller hinton broth. null

2011-03-30 | E-FPMI-23 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data